Share development opportunities with China and better protect the health of the Chinese public
Thomas Triomphe, Executive Vice President of Sanofi Vaccine Global Division of people's Daily online-International Channel. Thomas Triomphe, Executive Vice President of Sanofi Vaccine Global Division, published a signed article entitled "sharing Development opportunities with China to better protect the Health of the Chinese Public." Chinese public health awareness has also undergone significant changes, taking the initiative to carry out self-health management has become a new consensus in Chinese society, and help the Chinese public better protect their health. Sanofi will also continue to implement the localization operation strategy and increase investment in China, and continue to introduce more innovative products and innovative prevention measures. We look forward to the introduction of this product to the Chinese public as soon as possible. "We also hope that Chinese wisdom can bring more innovative solutions to the world, and we have established the Dawan area International Vaccine Innovation Center in Shenzhen. This is also the first innovation center in China that focuses on vaccine ecological innovation.
Source: people's Daily-International Channel
Thomas Triomphe, Executive Vice President, Global Division of Sanofi Vaccine
People's Network News Sanofi Vaccine Global Division Executive Vice President Thomas Triomphe published a signed article "sharing development opportunities with China to better protect the health of the Chinese public." The full text is as follows:
China's development has attracted a lot of attention in the past decade. We are pleased to see that with the continuous growth of investment in the medical and health field, China has achieved great-leap-forward development in many areas, such as the construction of the public health system and the improvement of the medical and health system. We are even more pleasantly surprised to note that while pursuing high-quality health products and services, the health awareness of the Chinese public has also changed significantly, and the positive health concept of "prevention first" has become more and more deeply rooted in the hearts of the people. through a healthy lifestyle, vaccination and other means, taking the initiative to carry out self-health management has become a new consensus of Chinese society.
It is Sanofi's important commitment in China to help the Chinese public better protect their health and radiate their lives with scientific miracles. Over the past 40 years since entering China, we have always been optimistic about the vitality and potential of the Chinese market. For example, by 2022, our children's joint vaccine products have cumulatively protected more than 12 million Chinese babies on Chinese mainland.
In the future, Sanofi will continue to implement the localization operation strategy and increase investment in China, and continue to introduce more innovative products and innovative preventive measures to better meet the Chinese public's yearning for a better life. At the Fifth Expo in 2022, Sanofi Vaccine brought Beyfortus (nirsevimab), the world's first and only respiratory syncytial virus (RSV) that can be widely used in newborns and infants, just hours after the product was first approved in the European Union. At present, it has obtained the "breakthrough therapeutic drug procedure" granted by the Drug Evaluation Center of China's State Drug Administration, and we look forward to seeing this product with the Chinese public as soon as possible in the future.
In addition, as an important innovation center in the world, China has made great achievements in artificial intelligence, 5G, biotechnology and other fields. We also hope that Chinese wisdom can bring more innovative solutions to the world. Therefore, we have established the Great Bay area International Vaccine Innovation Center in Shenzhen, which is also the first innovation center in China to focus on vaccine ecological innovation. We are also working with local partners in China to create 5G intelligent vaccination outpatient solutions and explore new ways of smart vaccination. At this Expo, we joined hands to learn that the new generation of intelligent unmanned vaccination module jointly created by Cloud Technology and the Chinese Academy of Sciences has attracted public attention.
In addition, we are also working with the Chinese government to actively explore an excellent example of building a healthy city. For example, Sanofi vaccine in 2021 will help Shenzhen to assess the medical and social value of free influenza vaccination among students and the elderly, enhance the government's confidence in influenza prevention and control and people's awareness of influenza vaccination, and establish a "Shenzhen model" for influenza prevention and control.
In the future, Sanofi, together with more local innovation partners in China, will more actively participate in and promote the development of preventive immunization in China. While sharing the development opportunities brought by China, Sanofi will also help to create a better tomorrow for mankind.
Finally, with the Spring Festival approaching in 2023, I would also like to wish Chinese friends a happy New year and all the best.